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Abstract 
Introduction: Tyrosine kinase inhibitors (TKIs) have dramatically changed the outcome of 
chronic myeloid leukemia (CML) patients. Recent research focused on TKI discontinuation 
after achieving a deep molecular response (DMR) has revealed that about half of the patients 
maintain the response. DMR is a key criterion for TKI discontinuation. Our retrospective, 
‘real-life’ study was aimed at to estimating the proportion of patients treated with first-line 
imatinib (IM) who achieved DMR and thus may be candidates for discontinuation of TKI 
treatment in a real life setting. 
Material and methods: Two hundred and twenty-three patients were enrolled. All patients 
started IM at 400 mg daily. The median age at the time of diagnosis was 57 years (range: 17–
92). 
Results: Eighty-five patients (43%) in the whole group achieved DMR. Early molecular 
response (EMR) was achieved by 136 (69%) patients and correlated with the DMR rate (53% 
with EMR vs 14% without, p < 0.001). Major molecular response (MMR) after a year of 
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treatment was confirmed in 108 (55%) patients, and was predictive for achieving DMR at any 
time (69% with MMR vs. 24% without, p < 0.001). 
Conclusion: DMR can be achieved in a significant proportion of patients in a real-life setting. 
We observed that both the achievement of an EMR at three months and MMR at 12 months 
were associated with a significant advantage in terms of DMR. 
Key words: chronic myeloid leukemia; imatinib; deep molecular response 
 
 
Introduction 
 
Chronic myeloid leukemia (CML) is the first myeloid neoplasm in which targeted therapy has 
been used. BCR-ABL kinase inhibitors (TKIs) have dramatically changed the outcome of 
CML patients, prolonging median survival to nearly normal life expectancy [1, 2]. The first 
TKI introduced for therapy was imatinib (IM). Over the following years, second generation 
TKIs of greater potency, namely nilotinib, dasatinib, and bosutinib, were introduced [3]. Over 
the time since TKIs were first used, the goals of treatment have evolved and become more 
stringent in optimizing treatment strategy. At present, the definition of optimal responses 
according to European LeukemiaNet (ELN) recommendations is: to achieve early molecular 
response (EMR); this is defined as BCR-ABL1 transcript reduction ≤ 10% at three months, ≤ 
1% or complete cytogenetics response (CCyR) at six months, ≤ 0.1% at 12 months, and ≤ 
0.01% at 24 months [4]. 
Several retrospective studies have shown that EMR at three months predicts 
significantly better long-term outcomes: event-free survival (EFS), progression-free survival 
(PFS), and overall survival (OS), and this is the case both in patients treated with IM and in 
patients treated with second-generation TKIs [1, 4]. Beyond EMR, two additional molecular 
responses have been defined as a prognostic factor for a long-term outcome: major molecular 
response (MMR: BCR-ABL < 0.1%), and deep molecular response (DMR), defined as BCR-
ABL ≤ 0.01%. The achievement of DMR is per se an important prognostic factor for the long-
term clinical outcome [5]. 
Recently, the possibility of discontinuing TKI treatment in CML patients with a deep 
molecular response (DMR) has been explored in clinical trials [6, 7]. Their results have 
indicated that about half of the patients maintain the response. Considering the potential side 
effects of lifelong exposure to TKIs, achieving treatment-free remission (TFR) has become a 
key goal of CML therapy [8] 
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Our study aimed to estimate the proportion of patients treated with first-line IM who 
achieve DMR and thus may be candidates for the discontinuation of TKI treatment. 
Additionally, we analyzed adherence to the recommendations according to monitoring 
cytogenetic and molecular response in a real-life setting. Furthermore, various clinical and 
laboratory parameters were investigated as potential predictors of DMR. 
 
Material and methods 
 
This retrospective analysis included newly diagnosed patients with chronic phase CML who 
received IM upfront in two Polish hematological centers between 2013 and 2018 outside of 
clinical trials. All living patients have given their written consent and the study was approved 
by the local ethics committee. Diagnostic criteria were defined according to the ELN criteria 
2013 [9]. Sokal, Hasford, and EUTOS scores were used to stratify risk at the time of diagnosis 
[10]. Molecular responses were assessed according to standard criteria and presented as 
International Scale (IS): MMR — BCR-ABLIS < 0.1%, MR4.0 — BCR-ABLIS < 0.01%, and 
MR4.5 — BCR-ABLIS < 0.001% [9]. DMR was defined as an achievement of at least MR4.0 or 
deeper. EMR was defined as BCR-ABL transcript reduction < 10% after three months of IM 
treatment [9]. Cytogenetics analyses were performed on at least 20 marrow metaphases. 
CCyR was defined according to the ELN recommendations 2013 [9]. The time points of 
response assessments were as follows: six and 12 months of IM treatment for a cytogenetic 
response, and three, six, nine, and 12 months for a molecular response. 
We used univariate logistic regression to estimate the impact of selected factors on the 
response. For each variable, the odds ratio and 95% confidence interval (95% CI) were 
calculated. Percentages were compared using the chi-squared test. All performed tests were 
two-sided, and results were considered statistically significant if p < 0.05. Stata 15 was used 
for statistical analyses. 
 
Results 
 
Patient characteristics 
Two hundred and twenty-three patients who were diagnosed with CML — CP between 2013 
and 2018 were enrolled in the study. All patients received IM at 400 mg daily. The median 
age at the time of diagnosis was 57 years (range: 17–92, with 36 [16%] patients > 70 years 
old). All patients had chromosome Philadelphia in the baseline cytogenetics. According to the 
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risk scores, the majority of patients were low risk (79% by Sokal, 71% by Hasford, and 89% 
by EUTOS). Median follow-up was 55 months (range: 12–100). The baseline characteristics 
of the group are set out in table I. 
 
 
Table I. Patient characteristics 
Characteristics N (%) 
Number of patients 223 
Gender  
Female 91 (41) 
Male 132 (59) 
Median age at diagnosis (range) 57 (17–92) 
Ph+clone  
With CCA 19 (8) 
Variant 8 (3) 
Type of transcript  
P210 
e14a2 
e13a2 
e13a3 
e14a3 
221 (99) 
144 (65) 
75 (34) 
1 (0.5) 
1 (0.5) 
P190 
e1a2 
1 (0,5) 
1 (0.5) 
P230 
e19a2 
1 (0,5) 
1 (0.5) 
Sokal score (total) 221 
Low 174 (79) 
Intermediate 36 (16) 
High 11 (5) 
Hasford score (total) 221 
Low 156 (71) 
Intermediate 51 (23) 
High 14 (6) 
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EUTOS score (total) 221 
Low 198 (89) 
High 23 (11) 
CCA — clonal cytogenetics abnormalities 
 
Imatinib tolerance 
IM was well tolerated. Adverse events (AEs) of any grade occurred in 63 (28%) patients. No 
cardiovascular event occurred. Imatinib was reduced to 300 mg in 32 patients (14%). The 
most common AEs are listed in table II. 
 
Table II. Main side effects of imatinib 
Side effect of imatinib Number of patients with 
side effect at any grade 
Number of patients 
with grade 4 toxicity 
N (%) 
63 (28%) 15 (7) 
Hematological toxicity 
Thrombocytopenia 7 (11%) 4 (27) 
Anemia 3 (4%) 1 (6) 
Neutropenia 6 (10%) 4 (27) 
Non-hematological toxicity  
Edema 13 (20%) 0 
Nausea, vomiting 10 (16%) 0 
Hepatic toxicity 4 (6%) 2 (13) 
Renal impairment 4 (6%) 1 (7) 
Skin rash 7 (11%) 3 (20) 
Bone/muscle pain 19 (30%) 0 
Other 22 (35%) 0 
 
Change for second-line treatment 
Overall, 81 patients (36%) discontinued imatinib and switched to a second-generation TKI. 
Among these, 66 (81%) were refractory to imatinib, eight (10%) switched due to imatinib 
intolerance, and seven (9%) for both reasons. The median time to switch was 12 months 
(range: 3–84). Nilotinib and dasatinib were chosen as second-line therapy with almost equal 
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frequency (49% and 48%, respectively), while only two patients (3%) switched to bosutinib. 
During the follow-up, four patients progressed to advanced phases of CML (three patients to 
accelerated phase [AP] and one to blast phase [BP]). 
 
Response evaluation 
Optimal response at particular time points was assessed according to the ELN 2013 [9]. The 
proportions of patients who had been tested are shown in table III. Almost all of the patients 
had cytogenetics and molecular analysis after six months of treatment (95%). Response 
assessment after 12 months of imatinib treatment was done by cytogenetics and molecular 
methods in 190 (85%), and 196 (87%) patients, respectively. 
 
Table III. Number of patients screened at designated time points 
Method of evaluation Time point of evaluation Number of screened 
patients (%) 
Cytogenetics 6th month 213 (95) 
12th month 190 (85) 
Molecular tests 3rd month 197 (88) 
6th month 214 (95) 
9th month 152 (68) 
12th month 196 (87) 
 
 
Response to IM therapy 
The optimal responses to imatinib according to the ELN2013 criteria are presented in table 
IV. The median time to achieve the deepest response was 12 months (range: 3–90). 
 
Table IV. Number of patients with optimal response according to ELN 2013 criteria 
Optimal responses according to ELN 
recommendations  
Total (%) 
CCyR at 6th month 151 (67.7) 
CCyR at 12th month 157 (70) 
MMR at 12th month  108 (48.4) 
> MR4 at any time point 47 (21) 
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≥ MR4.5 at any time point 48 (22%) 
CCyR — complete cytogenetic response; ELN — European LeukemiaNet; MMR — major 
molecular response; MR — molecular response 
 
At three months, 136 patients (69%) obtained EMR. In this group, 72 patients (53%) 
achieved DMR. The percentage of DMR in the group without optimal EMR was 14% (95% 
CI: 0.24–0.45, p < 0.001). After a year of treatment, MMR was confirmed in 108 patients 
(55%). In this subgroup, 75 patients (69%) achieved DMR at any time. In contrast, only 21 
(24%) patients without MMR after one year achieved DMR (95% CI: 0.43–0.65, p < 0.001). 
In general, during IM treatment 85 patients (43%) in the whole group achieved DMR. 
The percentage of patients with treatment failure at a particular time point, according 
to the ELN2013 recommendations, are presented in table V. In general, during imatinib 
treatment, 49 patients (22%) did not achieve MMR, and 25 (11%) did not reach PCyR. These 
patients were considered as refractory to imatinib and switched to second-generation TKI 
except for 10 patients (4%) who were still treated with imatinib because of their advanced age 
and comorbidities. They were considered as having clinical benefit although without an 
optimal response. Over the follow-up, four patients progressed to advanced phases of CML: 
three patients to AP and one to BP. All of the progressions occurred on imatinib. 
 
Table V. Number of patients with treatment failure according to ELN2013 criteria 
Treatment failure according to ELN 
recommendations 
Total (%) 
No CHR at 3 months 1 (0.5) 
No MCyR at 6 month 19 (9) 
BCR-ABL > 10% at 6 month 32 (14) 
No CCyR at 12 month 31 (14) 
BCR-ABL > 1% at 12 month 30 (13) 
CCyR — complete cytogenetic response; CHR — complete hematologic response; ELN — 
European LeukemiaNet; MCyR — major cytogenetic response 
 
Among 36 patients older than 70 years at the time of diagnosis, 50% achieved EMR, 
33% MMR after a year of treatment, and 30% achieved DMR. 
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We analyzed the impact of age, Sokal, Hasford, and EUTOS scores, and the 
achievement of EMR on response. Additionally, we analyzed whether the presence of clonal 
cytogenetic abnormalities (CCA) influenced cytogenetic responses at six and 12 months, and 
molecular response at three, six, and 12th months. In univariate analysis, only the achievement 
of EMR at three months predicted the chance of DMR (OR 5.88 [95% CI: 2.75–12.59], p < 
0.001). Other than that, a low Hasford score was associated with the probability of EMR 
achievement (OR 2.03 [95% CI: 1.04–3.97], p = 0.03). Other factors did not impact upon 
molecular or cytogenetic response at any time point. 
 
Discussion 
 
The main criterion for safe and appropriate TKI cessation is the achievement of DMR, 
defined as BCR-ABL1 ≤ 0.01% [3, 9]. Therefore, in routine clinical practice, it is crucial to 
monitor molecular response at designated time points following the ELN recommendations 
[9].  
The results of our study reveal that in a ‘real-life’ setting, compliance with monitoring 
recommendations is very good. Nearly 90% of patients had both molecular and cytogenetic 
testing in the proper time points. In contrast, Nicolinii et al. reported that among 418 CML 
patients included in a real-life retrospective study in France, molecular data was fully 
available for 294 patients (70%) [10]. In a real-life Italian study, the EMR data was available 
only in 61% of patients [11]. 
It has been shown that EMR is a strong predictor of outcome of CML patients 
regarding both PFS and OS [5]. Moreover, the achievement of DMR is influenced by the 
molecular response at three months of therapy. Marin et al. identified BCR-ABL of 0.61% at 
three months to be a discriminative landmark for the achievement of cumulative complete 
molecular remission with a difference of 85% vs. 2% at 8 years [12]. In our study, 69% of 
patients achieved optimal EMR. Among them, 53% achieved DMR at any time, whereas the 
percentage of DMR in the group without optimal EMR was only 14% (p < 0.001) which 
confirms the importance of a 3-month molecular response for DMR achievement. In two real-
life Italian studies, the percentage of optimal EMR on IM was similar and amounted to around 
80% [11, 13]. 
In our group, 55% of patients achieved MMR at 12 months. This is another important 
milestone in CML treatment, significant both for DMR and OS [5]. Sixty-nine percent of 
patients with MMR at 12 months achieved DMR later on. In contrast, only 24% of patients 
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who did not have MMR at 12 months achieved DMR (p < 0.001) at any time during imatinib 
treatment. In line with our results, Molica et al. observed MMR at 12 months in 57.1% of 
patients [13]. They underscored that among patients who had not achieved MMR at 12 
months, 42.7% never reached MMR during IM treatment. 
We have reported that 43% of patients achieved DMR (MR4 21%, ≥ MR4.5 22%) 
after five years of follow up. Our results are in line with previous real-life studies [8, 9]. 
Nevertheless, in the randomized German CML — Study IV, a significantly higher proportion 
of patients achieved DMR [1]. At 10 years, 59% of patients achieved MR5, 72% MR4.5, and 
81% MR4. However, it should be noted that the dose of IM was 800 mg and the follow-up 
period was longer. In the randomized IRIS study, the response rate of MR4.5 after five years 
follow-up was 40%, which was similar to our report, and after 10 years had increased to 63% 
[2]. 
Patients in clinical trials are selected according to eligibility criteria. The exclusion 
criteria are mainly associated with co-morbidities. Such preselection results in a lower age of 
the studied population. In our study, 16% of patients were > 70 years old. Although univariate 
analysis showed no relationship between age and DMR, the frequency of EMR and DMR was 
significantly lower in patients > 70 years old. This may have been associated with 
comorbidities, drug interactions, and the need to reduce the TKI dose due to toxicity. Despite 
this, 30% of older patients still achieved DMR. 
 
Conclusion 
 
Our study has shown that DMR can be achieved in a significant proportion of CML patients 
treated with IM as first-line therapy in a ‘real-life’ setting. We observed that both the 
achievement of an EMR at three months and MMR at 12 months were associated with a 
significant advantage in terms of DMR.  
Therefore, if these therapeutic goals are not achieved, for selected patients switching 
to a strong-acting second-generation TKI should be considered. 
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